NYSE - Nasdaq Real Time Price • USD
AbbVie Inc. (ABBV)
At close: May 31 at 4:05 PM EDT
After hours: May 31 at 7:59 PM EDT
Earnings Estimate
| CURRENCY IN USD | Current Qtr. (Jun 2024) | Next Qtr. (Sep 2024) | Current Year (2024) | Next Year (2025) |
|---|---|---|---|---|
| No. of Analysts | 19 | 19 | 21 | 21 |
| Avg. Estimate | 3.05 | 2.9 | 11.25 | 12.05 |
| Low Estimate | 2.99 | 2.81 | 11.02 | 11.4 |
| High Estimate | 3.11 | 2.98 | 11.4 | 12.71 |
| Year Ago EPS | 2.91 | 2.95 | 11.11 | 11.25 |
Revenue Estimate
| CURRENCY IN USD | Current Qtr. (Jun 2024) | Next Qtr. (Sep 2024) | Current Year (2024) | Next Year (2025) |
|---|---|---|---|---|
| No. of Analysts | 18 | 17 | 22 | 22 |
| Avg. Estimate | 14B | 14.17B | 55.22B | 58.34B |
| Low Estimate | 13.82B | 13.98B | 54.9B | 56.43B |
| High Estimate | 14.2B | 14.37B | 55.84B | 60.81B |
| Year Ago Sales | 13.87B | 13.71B | 54.32B | 55.22B |
| Sales Growth (year/est) | 1.00% | 3.40% | 1.70% | 5.70% |
Earnings History
| CURRENCY IN USD | 6/30/2023 | 9/30/2023 | 12/31/2023 | 3/31/2024 |
|---|---|---|---|---|
| EPS Est. | 2.81 | 2.86 | 2.77 | 2.23 |
| EPS Actual | 2.91 | 2.95 | 2.79 | 2.31 |
| Difference | 0.1 | 0.09 | 0.02 | 0.08 |
| Surprise % | 3.60% | 3.10% | 0.70% | 3.60% |
EPS Trend
| CURRENCY IN USD | Current Qtr. (Jun 2024) | Next Qtr. (Sep 2024) | Current Year (2024) | Next Year (2025) |
|---|---|---|---|---|
| Current Estimate | 3.05 | 2.9 | 11.25 | 12.05 |
| 7 Days Ago | 3.05 | 2.9 | 11.25 | 12.05 |
| 30 Days Ago | 3.05 | 2.9 | 11.24 | 12.02 |
| 60 Days Ago | 2.8 | 2.92 | 11.19 | 12.21 |
| 90 Days Ago | 2.8 | 2.93 | 11.19 | 12.21 |
EPS Revisions
| CURRENCY IN USD | Current Qtr. (Jun 2024) | Next Qtr. (Sep 2024) | Current Year (2024) | Next Year (2025) |
|---|---|---|---|---|
| Up Last 7 Days | -- | -- | -- | -- |
| Up Last 30 Days | 1 | 1 | 2 | 2 |
| Down Last 7 Days | -- | -- | -- | -- |
| Down Last 30 Days | -- | -- | 1 | 1 |
Growth Estimates
| CURRENCY IN USD | ABBV | Industry | Sector | S&P 500 |
|---|---|---|---|---|
| Current Qtr. | 4.80% | -- | -- | 8.90% |
| Next Qtr. | -1.70% | -- | -- | 11.40% |
| Current Year | 1.30% | -- | -- | 5.80% |
| Next Year | 7.10% | -- | -- | 12.60% |
| Next 5 Years (per annum) | 6.21% | -- | -- | 11.45% |
| Past 5 Years (per annum) | 5.57% | -- | -- | -- |
Research Analysis
Upgrades & Downgrades
| Initiated | Cantor Fitzgerald: Overweight | 5/17/2024 |
| Maintains | Barclays: Overweight to Overweight | 4/29/2024 |
| Maintains | BMO Capital: Outperform to Outperform | 4/29/2024 |
| Maintains | Barclays: Overweight to Overweight | 3/27/2024 |
| Maintains | Guggenheim: Buy to Buy | 3/22/2024 |
| Maintains | Truist Securities: Buy to Buy | 2/6/2024 |
Related Tickers
JNJ Johnson & Johnson
146.67
+0.96%
MRK Merck & Co., Inc.
125.54
+0.81%
BMY Bristol-Myers Squibb Company
41.09
+2.09%
PFE Pfizer Inc.
28.66
+1.63%
AMGN Amgen Inc.
305.85
+1.61%
LLY Eli Lilly and Company
820.34
+0.65%
GILD Gilead Sciences, Inc.
64.27
+0.30%
AZN AstraZeneca PLC
78.02
+1.63%
GSK GSK plc
44.77
+1.70%
NVS Novartis AG
103.13
+2.41%